Cargando…

Preventing Disused Bone Loss through Inhibition of Advanced Glycation End Products

Bone loss occurs in astronauts during long-term space flight, but the mechanisms are still unclear. We previously showed that advanced glycation end products (AGEs) were involved in microgravity-induced osteoporosis. Here, we investigated the improvement effects of blocking AGEs formation on microgr...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Cong-Jin, Yang, Xiao, Wang, Shou-Hui, Wu, Xin-Tong, Mao, Yan, Shi, Jing-Wen, Fan, Yu-Bo, Sun, Lian-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003672/
https://www.ncbi.nlm.nih.gov/pubmed/36902384
http://dx.doi.org/10.3390/ijms24054953
_version_ 1784904658718818304
author Liu, Cong-Jin
Yang, Xiao
Wang, Shou-Hui
Wu, Xin-Tong
Mao, Yan
Shi, Jing-Wen
Fan, Yu-Bo
Sun, Lian-Wen
author_facet Liu, Cong-Jin
Yang, Xiao
Wang, Shou-Hui
Wu, Xin-Tong
Mao, Yan
Shi, Jing-Wen
Fan, Yu-Bo
Sun, Lian-Wen
author_sort Liu, Cong-Jin
collection PubMed
description Bone loss occurs in astronauts during long-term space flight, but the mechanisms are still unclear. We previously showed that advanced glycation end products (AGEs) were involved in microgravity-induced osteoporosis. Here, we investigated the improvement effects of blocking AGEs formation on microgravity-induced bone loss by using the AGEs formation inhibitor, irbesartan. To achieve this objective, we used a tail-suspended (TS) rat model to simulate microgravity and treated the TS rats with 50 mg/kg/day irbesartan, as well as the fluorochrome biomarkers injected into rats to label dynamic bone formation. To assess the accumulation of AGEs, pentosidine (PEN), non-enzymatic cross-links (NE−xLR), and fluorescent AGEs (fAGEs) were identified in the bone; 8-hydroxydeoxyguanosine (8-OHdG) was analyzed for the reactive oxygen species (ROS) level in the bone. Meanwhile, bone mechanical properties, bone microstructure, and dynamic bone histomorphometry were tested for bone quality assessment, and Osterix and TRAP were immunofluorescences stained for the activities of osteoblastic and osteoclastic cells. Results showed AGEs increased significantly and 8-OHdG expression in bone showed an upward trend in TS rat hindlimbs. The bone quality (bone microstructure and mechanical properties) and bone formation process (dynamic bone formation and osteoblastic cells activities) were inhibited after tail-suspension, and showed a correlation with AGEs, suggesting the elevated AGEs contributed to the disused bone loss. After being treated with irbesartan, the increased AGEs and 8-OHdG expression were significantly inhibited, suggesting irbesartan may reduce ROS to inhibit dicarbonyl compounds, thus suppressing AGEs production after tail-suspension. The inhibition of AGEs can partially alter the bone remodeling process and improve bone quality. Both AGEs accumulation and bone alterations almost occurred in trabecular bone but not in cortical bone, suggesting AGEs effects on bone remodeling under microgravity are dependent on the biological milieu.
format Online
Article
Text
id pubmed-10003672
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100036722023-03-11 Preventing Disused Bone Loss through Inhibition of Advanced Glycation End Products Liu, Cong-Jin Yang, Xiao Wang, Shou-Hui Wu, Xin-Tong Mao, Yan Shi, Jing-Wen Fan, Yu-Bo Sun, Lian-Wen Int J Mol Sci Article Bone loss occurs in astronauts during long-term space flight, but the mechanisms are still unclear. We previously showed that advanced glycation end products (AGEs) were involved in microgravity-induced osteoporosis. Here, we investigated the improvement effects of blocking AGEs formation on microgravity-induced bone loss by using the AGEs formation inhibitor, irbesartan. To achieve this objective, we used a tail-suspended (TS) rat model to simulate microgravity and treated the TS rats with 50 mg/kg/day irbesartan, as well as the fluorochrome biomarkers injected into rats to label dynamic bone formation. To assess the accumulation of AGEs, pentosidine (PEN), non-enzymatic cross-links (NE−xLR), and fluorescent AGEs (fAGEs) were identified in the bone; 8-hydroxydeoxyguanosine (8-OHdG) was analyzed for the reactive oxygen species (ROS) level in the bone. Meanwhile, bone mechanical properties, bone microstructure, and dynamic bone histomorphometry were tested for bone quality assessment, and Osterix and TRAP were immunofluorescences stained for the activities of osteoblastic and osteoclastic cells. Results showed AGEs increased significantly and 8-OHdG expression in bone showed an upward trend in TS rat hindlimbs. The bone quality (bone microstructure and mechanical properties) and bone formation process (dynamic bone formation and osteoblastic cells activities) were inhibited after tail-suspension, and showed a correlation with AGEs, suggesting the elevated AGEs contributed to the disused bone loss. After being treated with irbesartan, the increased AGEs and 8-OHdG expression were significantly inhibited, suggesting irbesartan may reduce ROS to inhibit dicarbonyl compounds, thus suppressing AGEs production after tail-suspension. The inhibition of AGEs can partially alter the bone remodeling process and improve bone quality. Both AGEs accumulation and bone alterations almost occurred in trabecular bone but not in cortical bone, suggesting AGEs effects on bone remodeling under microgravity are dependent on the biological milieu. MDPI 2023-03-03 /pmc/articles/PMC10003672/ /pubmed/36902384 http://dx.doi.org/10.3390/ijms24054953 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Liu, Cong-Jin
Yang, Xiao
Wang, Shou-Hui
Wu, Xin-Tong
Mao, Yan
Shi, Jing-Wen
Fan, Yu-Bo
Sun, Lian-Wen
Preventing Disused Bone Loss through Inhibition of Advanced Glycation End Products
title Preventing Disused Bone Loss through Inhibition of Advanced Glycation End Products
title_full Preventing Disused Bone Loss through Inhibition of Advanced Glycation End Products
title_fullStr Preventing Disused Bone Loss through Inhibition of Advanced Glycation End Products
title_full_unstemmed Preventing Disused Bone Loss through Inhibition of Advanced Glycation End Products
title_short Preventing Disused Bone Loss through Inhibition of Advanced Glycation End Products
title_sort preventing disused bone loss through inhibition of advanced glycation end products
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003672/
https://www.ncbi.nlm.nih.gov/pubmed/36902384
http://dx.doi.org/10.3390/ijms24054953
work_keys_str_mv AT liucongjin preventingdisusedbonelossthroughinhibitionofadvancedglycationendproducts
AT yangxiao preventingdisusedbonelossthroughinhibitionofadvancedglycationendproducts
AT wangshouhui preventingdisusedbonelossthroughinhibitionofadvancedglycationendproducts
AT wuxintong preventingdisusedbonelossthroughinhibitionofadvancedglycationendproducts
AT maoyan preventingdisusedbonelossthroughinhibitionofadvancedglycationendproducts
AT shijingwen preventingdisusedbonelossthroughinhibitionofadvancedglycationendproducts
AT fanyubo preventingdisusedbonelossthroughinhibitionofadvancedglycationendproducts
AT sunlianwen preventingdisusedbonelossthroughinhibitionofadvancedglycationendproducts